Delving into the Latest Updates on Flurbiprofen Axetil with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Flurbiprofen axetil (JAN)

+ [5]

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Cancer PainPain, PostoperativePain+ [1]

Inactive Indication-

Originator Organization

Kaken Pharmaceutical Co., Ltd.

Active Organization

Shanxi Pude Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

Beijing Tide Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization

GUANGDONG JIABO PHARMACEUTICAL CO LTD

Drug Highest PhaseApproved

First Approval Date

Japan (27 Mar 1992),

Cancer PainPain, Postoperative

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC19H19FO4

InChIKeyALIVXCSEERJYHU-UHFFFAOYSA-N

CAS Registry91503-79-6

Primary objective: To compare the effectiveness of flurbiprofen axetil injection and the original drug flurbiprofen axetil injection (ROPION®) for postoperative analgesia in subjects. Secondary objective: To compare the safety of flurbiprofen axetil injection and the original drug flurbiprofen axetil injection (ROPION®) for postoperative analgesia in subjects.

Start Date18 Jul 2023

Sponsor / Collaborator

Chongqing Yao Pharmaceutical Co., Ltd.

100 Clinical Results associated with Flurbiprofen Axetil

Login to view more data

100 Translational Medicine associated with Flurbiprofen Axetil

Login to view more data

100 Patents (Medical) associated with Flurbiprofen Axetil

Login to view more data

572

Literatures (Medical) associated with Flurbiprofen Axetil

01 Jan 2025·Cell Biology International

Flurbiprofen axetil is involved in basal‐like breast cancer metastasis via suppressing the MEK/ERK signaling pathway

Article

Author: Zhu, Yalin ; Wang, Shuoer ; Gong, Yi ; Yao, Ying ; Wang, Yifei ; Zhang, Yan ; Cao, Jianping ; Miao, Xiaoyong ; Jiang, Zhengyu

AbstractFlurbiprofen axetil is commonly utilized in clinical practice as one of the nonsteroidal anti‐inflammatory drugs (NSAIDs) and is included in multimodal analgesia regimens postbreast cancer surgery. Numerous NSAIDs have been studied for their potential to both promote and inhibit cancer. Given the variability in their effects on tumors, further investigation into the specific role of flurbiprofen axetil is warranted. Therefore, the primary objective of this study was to assess the impact of flurbiprofen axetil on basal‐like breast cancer (BLBC) metastasis and elucidate the underlying molecular mechanisms involved. The BLBC metastasis mouse model was established by caudal vein injection of tumor cells. The lung metastasis of breast cancer in mice and the effect of flurbiprofen axetil were assessed by in vivo bioluminescence imaging, hematoxylin and eosin staining and immunohistochemistry. In vitro, the results of flurbiprofen axetil on the proliferation, migration, and invasion of MDA‐MB‐231 human breast cancer cells and BT‐549 human breast cancer cells were assessed by colony formation assay and transwell assay. The effects of flurbiprofen axetil on several tumor metastasis‐related signaling pathway proteins were examined by western blot, and the reversal extent of the flurbiprofen axetil effect by Ro 67‐7476 (ERK phosphorylation agonist) was detected by transwell assay. The results showed that flurbiprofen axetil significantly inhibited BLBC lung metastasis in mice. Flurbiprofen axetil similarly inhibited breast cancer cell migration and invasion in vitro but did not affect their proliferation. Mechanistic investigations have revealed that flurbiprofen axetil exerts a noteworthy inhibitory influence on the MEK/ERK pathway while exhibiting no significant alteration in the expression of other pathway proteins intricately associated with epithelial–mesenchymal transition. In conclusion, the inhibitory effect of flurbiprofen axetil on BLBC metastasis is characterized by its selectivity in targeting the MEK/ERK signaling pathway rather than exerting a broad impact on the global signaling pathway.

01 Oct 2024·Anaesthesia

Comparison of opioid‐free and opioid‐inclusive propofol anaesthesia for thyroid and parathyroid surgery: a randomised controlled trial

Article

Author: Liu, Hong ; Zhu, Ya‐Juan ; Shan, Xi‐Sheng ; Ji, Fu‐Hai ; Wang, Dan ; Sun, Yan ; Peng, Ke

SummaryBackgroundPostoperative nausea and vomiting occur frequently following thyroid and parathyroid surgery and are associated with worse patient outcomes. We hypothesised that opioid‐free propofol anaesthesia would reduce the incidence of postoperative nausea and vomiting compared with opioid‐inclusive propofol anaesthesia in patients undergoing these procedures.MethodsWe conducted a randomised, double‐blinded controlled trial in adult patients scheduled to undergo thyroid and parathyroid surgery at two medical centres in mainland China. Patients were allocated randomly (1:1, stratified by sex and trial site) to an opioid‐free anaesthesia group (esketamine, lidocaine, dexmedetomidine and propofol) or an opioid‐inclusive group (sufentanil and propofol). Propofol infusions were titrated to bispectral index 45–55. Patients received prophylaxis for nausea and vomiting using dexamethasone and ondansetron and multimodal analgesia with paracetamol and flurbiprofen axetil. The primary outcome was the incidence of postoperative nausea and vomiting in the first 48 h after surgery.ResultsWe assessed 557 patients for eligibility and 394 completed this trial. The incidence of postoperative nausea and vomiting in the first postoperative 48 h was lower in the opioid‐free anaesthesia group (10/197, 5%) compared with opioid‐inclusive group (47/197, 24%) (OR (95%CI) 0.17 (0.08–0.35), p < 0.001), yielding a number needed to treat of 5.3. Additionally, opioid‐free propofol anaesthesia was associated with a reduced need for rescue anti‐emetics, lower rates of hypotension and desaturation after tracheal extubation, and higher patient satisfaction. Time to tracheal extubation was prolonged slightly in the opioid‐free group. The two groups had similar postoperative pain scores and 30‐day outcomes.DiscussionOpioid‐free propofol anaesthesia reduced postoperative nausea and vomiting in patients undergoing thyroid and parathyroid surgery. An opioid‐free anaesthetic regimen can optimise anaesthetic care during thyroid and parathyroid surgery.

02 Aug 2024·Medicine

Thoracoscopic wedge resection of the upper lobe of the left lung achieved by a new approach of laryngeal mask general anesthesia with preservation of spontaneous breathing: A case report

Article

Author: Xie, Mengran ; Pei, Huanshuang ; Meng, Yu

Introduction:General laryngeal mask anesthesia with the preservation of spontaneous breathing has accelerated the advancement of the enhanced recovery after surgery concept in thoracoscopic surgery. However, the need for increased doses of anesthetic drugs to reduce laryngeal mask airway (LMA) stimulation poses challenges due to the increased risk of hypotension, respiratory depression, susceptibility to hypoxemia, and carbon dioxide retention, particularly in the lateral position.Patient concerns:During the perioperative period, reducing the dose of anesthetic drugs while simultaneously improving LMA tolerance and preventing circulatory and respiratory depression poses a challenge.Diagnoses:The patient was diagnosed with a nodule in the upper lobe of the left lung.Interventions:In this case, we chose remimazolam sedation, which mildly inhibits circulatory respiration, and used mucosal surface anesthesia in the pharynx. This approach improved the patient’s tolerance to LMA, reduced the dose of anesthetic drugs, and facilitated the successful thoracoscopic wedge resection of the upper lobe of the left lung with preservation of spontaneous respiration.Outcomes:During 2 weeks follow-up, the patient recovered satisfactorily and did not report any discomfort.Conclusion:We used pharyngeal mucosal surface anesthesia and thoracic paravertebral nerve block in combination with remimazolam sedation to provide precise analgesia, moderate sedation, and successful LMA general anesthesia with preservation of spontaneous respiration in patients undergoing thoracoscopic pulmonary wedge resection.

100 Deals associated with Flurbiprofen Axetil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01475	Flurbiprofen Axetil	M01AE09 M02AA19 R02AX01 S01BC04	DB14938

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Kaken Pharmaceutical Co., Ltd.	27 Mar 1992
Pain, Postoperative	Japan	Kaken Pharmaceutical Co., Ltd.	27 Mar 1992

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 3	China	Shanxi Pude Pharmaceutical Co., Ltd.	02 Jan 2018
Acute rise of fever	Phase 2	China	Shanxi Pude Pharmaceutical Co., Ltd.	29 Dec 2017
Acute rise of fever	Phase 2	China	Beijing Jingke Tailai Technology Co., Ltd.	29 Dec 2017
Pain, Postoperative	Discovery	China	GUANGDONG JIABO PHARMACEUTICAL CO LTD	05 Jan 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR-IPR-16008133 (Pubmed \| Anesth Analg)	Not Applicable	-	200	Flurbiprofen axetil	vmluqghigv(ssjtpzbaqv) = fdicckimri hjeaedfqjp (xpqxiepdrf ) View more	Positive	01 Oct 2017
				Placebo	vmluqghigv(ssjtpzbaqv) = vmjlbvgpgl hjeaedfqjp (xpqxiepdrf ) View more
NCT02043366 (CTgov)	Not Applicable	Pain \| Anesthesia \| Hyperalgesia	180	Normal saline+Remifentanil (Normal Saline)	dqunyeyrqx(dmmcwffhnk) = ienahhrcje orngbxbwlu (wemlgowina, rpmhtmjuec - uppnuhcmch) View more	-	28 Sep 2015
				Flurbiprofen axetil+Remifentanil (Flurbiprofen AxetilⅠ)	dqunyeyrqx(dmmcwffhnk) = vhucjefwkx orngbxbwlu (wemlgowina, covvxnvkxc - sdbiclvagu) View more